Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.

abstract：:Schizophrenia is a major mental illness with a lifetime prevalence of about 1%. Antipsychotic drugs, with a primary mechanism of action that involves dopamine receptor blockade, are the mainstay in the treatment of the disorder. However, despite optimum antipsychotic treatment, few patients return to pre-morbid levels...

journal_title：Expert review of clinical pharmacology

authors： Andrade C

更新日期：2016-01-01 00:00:00

abstract：:Introduction: Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease characterized by synovitis as well as symmetric and destructive arthropathy. Although several disease modified antirheumatic-drugs (DMARDs) have widely used in clinical practice, certain patients are nonresponsive to or cannot take suc...

journal_title：Expert review of clinical pharmacology

authors： Qiu Q,Feng Q,Tan X,Guo M

更新日期：2019-06-01 00:00:00

abstract：INTRODUCTION:Allogeneic hematopoietic cell transplants (allo-HCT) recipients are at the high-risk of reactivation of cytomegalovirus (CMV), and reactivation is associated with significant morbidity and mortality. Although available anti-CMV therapies may be effective for the prevention of CMV, they are plagued by unacc...

journal_title：Expert review of clinical pharmacology

authors： Foolad F,Aitken SL,Chemaly RF

更新日期：2018-10-01 00:00:00

abstract：INTRODUCTION:Therapeutic efficiency of NSAID is handicapped by ongoing discussion of cardiovascular (CV) safety. Areas covered: We update meta-analyses on NSAIDs in patients with and without cardiovascular (CV) diseases and analyse the association between NSAIDs and cardiovascular events in patients with inflammation. ...

journal_title：Expert review of clinical pharmacology

authors： Zingler G,Hermann B,Fischer T,Herdegen T

更新日期：2016-11-01 00:00:00

abstract：:'IDegLira' combines insulin degludec (IDeg) with the glucagon-like peptide-1 analog liraglutide (Lira) at a ratio of 1 unit IDeg to 0.036 mg Lira. The two components have complementary therapeutic actions for the treatment of Type 2 diabetes. Studies have shown that combinations of basal insulin with glucagon-like pep...

journal_title：Expert review of clinical pharmacology

authors： Simpson R,King A

更新日期：2015-03-01 00:00:00

abstract：INTRODUCTION:The immune system can restrain or promote cancer development and growth. Antibodies targeting immune checkpoints have revolutionized cancer treatment. Among the best responses have been in non-small cell lung cancer (NSCLC) which is largely caused by chronic exposure to carcinogens; associated with high ne...

journal_title：Expert review of clinical pharmacology

authors： Santini FC,Rudin CM

更新日期：2017-09-01 00:00:00

abstract：:Inflammation plays a critical role in host defense, maintaining cellular and tissue integrity following chemical, physical and biological insults. Inflammation presents in a variety of acute and chronic disease states and can contribute to disease resolution or progression depending upon the type, magnitude and durati...

journal_title：Expert review of clinical pharmacology

authors： Cressman AM,Petrovic V,Piquette-Miller M

更新日期：2012-01-01 00:00:00

abstract：:Magnetic nanoparticles (MNPs) represent a promising nanomaterial for the targeted therapy and imaging of malignant brain tumors. Conjugation of peptides or antibodies to the surface of MNPs allows direct targeting of the tumor cell surface and potential disruption of active signaling pathways present in tumor cells. D...

journal_title：Expert review of clinical pharmacology

authors： Wankhede M,Bouras A,Kaluzova M,Hadjipanayis CG

更新日期：2012-03-01 00:00:00

abstract：INTRODUCTION:The incidence of kidney dysfunction increases with age and is highly prevalent among patients with hypertension. Since many therapeutic compounds are primarily eliminated through the kidneys, impaired renal function can have negative consequences on drug disposition, efficacy and safety. Therefore, regulat...

journal_title：Expert review of clinical pharmacology

authors： Paglialunga S,Offman E,Ichhpurani N,Marbury TC,Morimoto BH

更新日期：2017-03-01 00:00:00

abstract：INTRODUCTION:Diabetes mellitus is associated with increased cardiovascular disease (CVD) risk. Areas covered: Main goal of hypolipidemic treatment in diabetic patients is low-density lipoprotein cholesterol (LDL-C) lowering with the use of statins. Addition of ezetimibe is useful in diabetic patients who cannot achieve...

journal_title：Expert review of clinical pharmacology

authors： Filippatos TD,Florentin M,Georgoula M,Elisaf MS

更新日期：2017-02-01 00:00:00

abstract：:The thermo transient receptor potential (TRP) ion channels, a recently discovered family of ion channels activated by temperature, are expressed in primary sensory nerve terminals, where they provide information regarding thermal changes in the environment. Six thermo-TRPs have been characterized to date: TRPV1-4, whi...

journal_title：Expert review of clinical pharmacology

authors： Vay L,Gu C,McNaughton PA

更新日期：2010-09-01 00:00:00

abstract：INTRODUCTION:Dapsone is a sulfone drug used to treat infectious conditions and also numerous dermatologic diseases. Fixed drug eruption is a distinctive adverse cutaneous reaction associated with the initial administration and subsequent delivery of a specific agent. Areas covered: The authors preformed a literature se...

journal_title：Expert review of clinical pharmacology

authors： Garcia D,Cohen PR

更新日期：2017-07-01 00:00:00

abstract：:RNAi is a powerful gene silencing process that holds great promise in cancer therapy by the use of siRNA. The aim of this review is to give an outline on different approaches to deliver siRNA and to describe the advantages and disadvantages of these systems. The prospects for siRNA are to be substantially better than ...

journal_title：Expert review of clinical pharmacology

authors： Ali HM,Urbinati G,Raouane M,Massaad-Massade L

更新日期：2012-07-01 00:00:00

abstract：:Naltrexone-bupropion is a recently approved drug combination for chronic weight management. In this article, we discuss the rationale for its use as a combination followed by a comprehensive review of safety and efficacy data from major preclinical, phase II and III clinical trials. ...

journal_title：Expert review of clinical pharmacology

authors： Ali KF,Shukla AP,Aronne LJ

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:The broad use of immunotherapy is revolutionizing the treatment paradigms of many solid tumors. Although chemotherapy remains the treatment backbone for advanced gastric cancer, improvements in its molecular characterization and progresses in understanding its underpinning biology have supported clinical d...

journal_title：Expert review of clinical pharmacology

authors： Bonotto M,Garattini SK,Basile D,Ongaro E,Fanotto V,Cattaneo M,Cortiula F,Iacono D,Cardellino GG,Pella N,Fasola G,Antonuzzo L,Silvestris N,Aprile G

更新日期：2017-06-01 00:00:00

abstract：INTRODUCTION:Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. Despite the known clinical efficacy in relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn from the market in 2010 due to increased e...

journal_title：Expert review of clinical pharmacology

authors： Baron J,Wang ES

更新日期：2018-06-01 00:00:00

abstract：:Introduction: Combined antiretroviral therapy (cART) has transformed an inexorably fatal disease into a chronic pathology, shifting the focus of research from the control of viral replication to the possibility of HIV cure. Areas covered: The present review assesses the principal pharmacological strategies that have b...

journal_title：Expert review of clinical pharmacology

authors： Giacomelli A,de Rose S,Rusconi S

更新日期：2019-01-01 00:00:00

abstract：INTRODUCTION:The Pharmacokinetics/pharmacodynamics (PK/PD) relationships with cytotoxics are usually based on a steepening concentration-effect relationship; the greater the drug amount, the greater the effect. The Maximum Tolerated Dose paradigm, finding the balance between efficacy, while keeping toxicities at their ...

journal_title：Expert review of clinical pharmacology

authors： Rodallec A,Fanciullino R,Lacarelle B,Ciccolini J

更新日期：2018-06-01 00:00:00

abstract：INTRODUCTION:Large-scale epidemiological studies on Greenlandic, Canadian and Alaskan Eskimos have examined the health benefits of omega-3 fatty acids consumed as part of the diet, and found statistically significant relative reduction in cardiovascular risk in people consuming omega-3 fatty acids. Areas covered: This ...

journal_title：Expert review of clinical pharmacology

authors： Watanabe Y,Tatsuno I

更新日期：2017-08-01 00:00:00

abstract：:Introduction: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squamous cell carcinoma (CSCC). Cemiplimab is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1). Cemiplimab blocks T-cell ina...

journal_title：Expert review of clinical pharmacology

authors： Ahmed SR,Petersen E,Patel R,Migden MR

更新日期：2019-10-01 00:00:00

abstract：:G-quadruplexes are non-Watson-Crick four-stranded nucleic acid structures. Recent evidence points toward their existence in vivo and their implication in various biological processes. Over the past two decades, small molecules have been developed to specifically and selectively target these structures in order to diss...

journal_title：Expert review of clinical pharmacology

authors： Müller S,Rodriguez R

更新日期：2014-09-01 00:00:00

abstract：:Introduction: An important gap within modern medicine is the lack of enough comparative effectiveness research of marketed medicines. Low-risk pragmatic randomized controlled trials (pRCTs) are those conducted resembling usual clinical practice that poses no or minimal incremental risk compared with normal clinical pr...

journal_title：Expert review of clinical pharmacology

authors： Dal-Ré R

更新日期：2020-03-01 00:00:00

abstract：:Introduction: Dementia is the 7th leading cause of death that imposes a significant financial and service burden on the global population. Presently, only symptomatic care exists for cognitive loss, such as Alzheimer's disease.Areas covered: Given the advancing age of the global population, it becomes imperative to de...

journal_title：Expert review of clinical pharmacology

authors： Maiese K

更新日期：2020-01-01 00:00:00

abstract：:Sugammadex, a modified γ-cyclodextrin, is the first selective relaxant binding agent. Sugammadex forms very tight complexes in a 1:1 ratio with steroidal neuromuscular blocking agents (rocuronium > vecuronium > pancuronium). This guest-host complex, which exists in equilibrium, is stable because of its very high assoc...

journal_title：Expert review of clinical pharmacology

authors： Naguib M,Brull SJ

更新日期：2009-01-01 00:00:00

abstract：:Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review ...

journal_title：Expert review of clinical pharmacology

authors： Jaleel T,Elmets C,Weinkle A,Kassira S,Elewski B

更新日期：2016-01-01 00:00:00

abstract：:Rosacea is a chronic inflammatory dermatologic condition that can often be disfiguring with significant negative impact on patients' quality of life. Sanrosa (brimonidine tartate) is a novel therapeutic agent targeting the facial flushing and erythema of rosacea through its α₂ adrenergic receptor agonist activity. The...

journal_title：Expert review of clinical pharmacology

authors： Tong LX,Moore AY

更新日期：2014-09-01 00:00:00

abstract：:Knee osteoarthritis is the most common form of arthritis. Given the aging of the world's population, the burden of this disease is expected to increase significantly over the next few decades. As a pharmacological agent, glucosamine has been investigated for the treatment of symptoms and progression of knee osteoarthr...

journal_title：Expert review of clinical pharmacology

authors： Altman RD

更新日期：2009-07-01 00:00:00

abstract：:Methotrexate is an antifolate agent used in the treatment of various cancers and some autoimmune diseases. In oncology, methotrexate is frequently administered at a high dose (>1 g/m(2)) and comes with various procedures to reduce the occurrence of toxicity and particularly to ensure optimal renal elimination. Drug-dr...

journal_title：Expert review of clinical pharmacology

authors： Levêque D,Santucci R,Gourieux B,Herbrecht R

更新日期：2011-11-01 00:00:00

abstract：:Data from clinical trials, retrospective and cross-sectional studies have quantified the metabolic changes associated with long-term use of antiepileptic drugs (AEDs). AEDs can be associated with weight gain or weight loss, although most are weight neutral. Weight gain is not only a cosmetic problem but also a risk fo...

journal_title：Expert review of clinical pharmacology

authors： Hamed SA

更新日期：2015-01-01 00:00:00

abstract：:Calcineurin inhibitors are widely used as maintenance immunosuppressants in solid-organ transplantation to minimize the risk of allograft rejection. Although the use of these agents has transformed the outcomes for patient and graft survival, this has come at a cost, notably the well-known adverse events of nephrotoxi...

journal_title：Expert review of clinical pharmacology

authors： Garcia-Saenz-de-Sicilia M,Mukherjee S

更新日期：2012-09-01 00:00:00